A Phase 4 interventional study of Berberine plus lifestyle intervention and Placebo plus lifestyle intervention in PreDiabetes, Abdominal Obesity and Hypertension, sponsored by China National Center for Cardiovascular Diseases. Active, not recruiting at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by China National Center for Cardiovascular Diseases · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Prediabetic State with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Prediabetic State · China.
Among the 51 studies in Prediabetic State with a site in China, this one is the 4th largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2023, is one of 8 in phase 4, reaches primary completion later than 8 of the 24 other live ones, and was the 23rd registered.
919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.
Browse Prediabetic State studies →24 of the 51 studies in Prediabetic State with a site in China are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in China, United States, Argentina and 9 more countries
Ages 18+
Yang Zhang · Sites in China
Ages 60–79
Zhujiang Hospital · Sites in China
Ages 18–60
Beijing Anzhen Hospital · Sites in China
Ages 18+ · Healthy volunteers
Hudson Biotech · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 3 · Phase 4 8
First in 2008; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,024 is above the median of 62 across 763 interventional studies indexed under Prediabetic State.
Median enrollment 160 across the 44 interventional studies, 2,800 across the 7 observational. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 51 have an industry lead sponsor. The 10 most frequent:
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
China National Center for Cardiovascular Diseases has 1 study filed under Prediabetic State — fewer than ten, so there is no comparison to draw.
12 of the studies in Prediabetic State with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06448130Shandong Provincial HospitalHenagliflozin's Impact on Prediabetes Remission | 2026-12 |
| NCT07289880The First Affiliated Hospital of Guangdong Pharmaceutical UniversityEfficacy of Diacylglycerol Oil on Metabolic Risk Factors in Prediabetes | 2026-12-01 |
| NCT05749874China National Center for Cardiovascular DiseasesEffects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | 2026-12-31 |
| NCT06958640China-Japan Friendship HospitalDa Qing Offspring Study | 2026-12-31 |
| NCT07271745Chunyan MaMulticenter Study on Early Arterial Changes in Prediabetic Patients Evaluated by Ultra-High-Frequency Ultrasound | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 51 studies in Prediabetic State with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, double-blinded, randomized controlled trial aims to evaluate the effect of berberine on preventing cardiovascular disease and diabetes mellitus among individuals with high cardiometabolic risk in China.
The trial aims to evaluate the efficacy and safety of berberine treatment for individuals with high cardiometabolic risk. Potential eligible patients will be recruited from about 100 medical centers in China. After a 4-to-6-week run-in period with berberine, all the eligible participants will be randomized (1:1) to berberine 500mg twice a day plus lifestyle intervention (Arm A) or placebo plus lifestyle intervention (Arm B). The participants will be followed up at month 3 and month 6, and once every 3 months thereafter, and be followed up for 3 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Berberine hydrochloride plus lifestyle intervention
Drug: Berberine plus lifestyle intervention
Placebo plus lifestyle intervention
Behavioral: Placebo plus lifestyle intervention
berberine hydrochloride 500mg twice a day plus lifestyle intervention. Lifestyle intervention is based on Chinese guideline for primary prevention of cardiovascular diseases, and Chinese guideline for management of type 2 diabetes mellitus, coronary heart disease, myocardial infarction and stroke. Intervention includes health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc.
Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention. Lifestyle intervention is based on Chinese guideline for primary prevention of cardiovascular diseases, and Chinese guideline for management of type 2 diabetes mellitus, coronary heart disease, myocardial infarction and stroke. Intervention includes health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc.
The distribution of glycemic status at 1 year after randomization
Categorized as normal glucose metabolism, prediabetes, and diabetes
Time frame: Intervention Period: 1 year
Changes of glycemic-related parameters
Including hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), homeostasis model assessment of insulin resistance (HOMA-IR), and homeostasis model assessment of β-cell function (HOMA-β)
Time frame: Intervention Period: 1 year
Changes of lipid-related parameters
Including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and lipoprotein(a)
Time frame: Intervention Period: 1 year
Change of inflammation-related marker
Including high-sensitivity C-reactive protein (hs-CRP)
Time frame: Intervention Period: 1 year
Change of physical examination measures
Including body mass index (BMI) and waist circumference
Time frame: Intervention Period: 1 year
Changes of other parameters
Including urinary albumin-to-creatinine ratio (UACR), serum uric acid, and metabolic syndrome score
Time frame: Intervention Period: 1 year
Change of depressive symptoms
Measured by Patient Health Questionnaire-9 (PHQ-9)
Time frame: Intervention Period: 1 year
Time to first occurrence of composite endpoint of major cardiovascular event and diabetes
cardiovascular death, non-hemorrhagic stroke, myocardial infarction, arterial revascularization, and diabetes
Time frame: Intervention Period: 1 year
Time to new-onset diabetes
Diabetes is determined by oral glucose tolerance test, clinical diagnosis or use of glucose-lowering medications.
Time frame: Intervention Period: 1 year
Normalization of glucose parameters
Meeting all three criteria: 1) Fasting plasma glucose (FPG)\<6.1 mmol/L; 2) 2-hour postprandial blood glucose (2hPG)\<7.8 mmol/L; 3) HbA1c\<5.7%.
Time frame: Intervention Period: 1 year
Time to newly diagnosed cancer
all events of cancer or classified by primary sites
Time frame: Intervention Period: 1 year
Exploratory biomarker analyses
Including serum trimethylamine, trimethylamine N-oxide, dopamine, berberine metabolites, and lipidomics analyses; urinary berberine metabolite analyses; and gut microbiota sequencing analyses.
Time frame: Intervention Period: 1 year
Time to first occurrence of composite endpoint of major cardiovascular event and diabetes
cardiovascular death, non-hemorrhagic stroke, myocardial infarction, arterial revascularization, and diabetes
Time frame: Entire follow-up period: 4 years
Time to new-onset diabetes
Diabetes is determined by oral glucose tolerance test, clinical diagnosis or use of glucose-lowering medications.
Time frame: Entire follow-up period: 4 years
Time to first occurrence of composite endpoint of major cardiovascular event 1
cardiovascular death, non-hemorrhagic stroke, myocardial infarction, arterial revascularization
Time frame: Entire follow-up period: 4 years
Time to first occurrence of composite endpoint of major cardiovascular event 2
cardiovascular death, non-hemorrhagic stroke, myocardial infarction
Time frame: Entire follow-up period: 4 years
Time to newly diagnosed cancer
all events of cancer or classified by primary sites
Time frame: Entire follow-up period: 4 years
Subgroup analysis 1 for primary outcome measure
Age (\<55,55-65,≥65)
Time frame: Intervention Period: 1 year
Subgroup analysis 2 for primary outcome measure
Sex (male, female)
Time frame: Intervention Period: 1 year
Subgroup analysis 3 for primary outcome measure
Body mass index (\<28kg/m2, ≥28kg/m2)
Time frame: Intervention Period: 1 year
Subgroup analysis 4 for primary outcome measure
Statin use (yes, no)
Time frame: Intervention Period: 1 year
Subgroup analysis 5 for primary outcome measure
HbA1c median
Time frame: Intervention Period: 1 year
Subgroup analysis 6 for primary outcome measure
Hs-CRP tertiles
Time frame: Intervention Period: 1 year
Subgroup analysis 7 for primary outcome measure
LDL-C tertiles
Time frame: Intervention Period: 1 year
Subgroup analysis 8 for primary outcome measure
Triglyceride tertiles
Time frame: Intervention Period: 1 year
Subgroup analysis 9 for primary outcome measure
HDL-C tertiles
Time frame: Intervention Period: 1 year
Safety assessment during the intervention period
Including serious adverse events, non-serious adverse events of special interest, and treatment discontinuation for any reason
Time frame: Intervention Period: 1 year
Plan to share: Undecided — All the IPD that underlie results in the publication with study protocol and SAP will be shared to the public on the study website upon request with a protocol after approval from the ABCD steering committee. The access criteria and URL of the study website is not established yet.
Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.
Of 30 phase 4 interventional studies under Prediabetic State, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 47. This study's planned 38 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →